Achaogen Gets FDA Breakthrough Therapy Status for Plazomicin
Achaogen (AKAO) Achaogen’s Plazomicin is Granted Breakthrough Therapy Designation for Bloodstream Infections On May 23rd, Achaogen (NasdaqGM: AKAO) announced that the FDA granted plazomicin Breakthrough Therapy Designation (BTD) for the bloodstream infection (BSI) indication.
The Company is developing plazomicin, a novel aminoglycoside antibiotic, for the treatment of multi-drug resistant (MDR) gram-negative infections. Achaogen has reported positive results from the EPIC and CARE Phase III studies, paving the way for a New Drug Application (NDA) submission for plazomicin in the second half of 2017. BTD allows the Company to have greater communication with the FDA, and may enable a quicker regulatory review process. The granting of BTD for BSIs suggest that the FDA takes a positive view of the CARE data and may be willing to allow its inclusion into the drug’s label.
¦ BTD Designation for BSI Suggests FDA Takes Positive View of CARE Data. Due to slower-than-expected enrollment, Achaogen stopped the CARE Phase III trial early to coincide with the readout from the EPIC study. Although the CARE study includes a small number of patients, the Company plans to include CARE data in the NDA and plans to discuss its inclusion in the drug’s label, which would likely promote the use of plazomicin to treat a broader subset of MDR infections.
At the 2017 meeting of the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Achaogen presented data from the subset of patients from cohort 1 of the CARE study with BSIs, which made up roughly 80% of the CARE study population. Since the FDA historically has approved antibiotic indications based on infection type not pathogen type, our expectation was that Achaogen’s ability to present a robust and supportive BSI dataset would likely help in their discussions with regulators. In our view, the granting of BTD for the BSI indication suggest that the FDA has a positive view of the CARE data and may be amenable to its inclusion in the plazomicin label.
¦ BTD Could Accelerate Approval Process. Achaogen plans to submit an NDA in the second half of 2017 supported by data from the EPIC and CARE Phase III studies. The Company has Fast Track, Qualified Infectious Disease Product (QIDP), and now Breakthrough Therapy designations, which could reduce the timeline to a potential commercial launch if approved. The NDA for plazomicin, expected to be filed in the second half of 2017, may be reviewed in as little as 6 months under the priority review process
Kiwi ( sorry ..unable to link and credit source ...except to say its not Streetsweeper
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.